Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis

Youssef, Mohamed; Wely, Madelon van; Aboulfoutouh, Ismail; El-Khyat, Walid; Veen, Fulco van der; Al-Inany, Hesham

doi:10.1016/j.fertnstert.2012.01.092

Cited by 44 publications

(24 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Results offered by the pooled analysis of this meta-analysis are compatible with the notion that proper exposure to corifollitropin alfa results in IVF outcome comparable to that observed with rFSH. This concept is in line with conclusions provided by two previously published meta-analyses [10, 11]. As a novel aspect, this meta-analysis included RCTs on two specific subpopulations of IVF patients, i.e.…”

Section: Discussionsupporting

confidence: 73%

“…Excluded studies included retrospective and uncontrolled studies, editorials and reviews. The search results were cross-checked against papers considered in previous meta-analyses [10, 11]. The target population was composed of infertile couples with any infertility factor undergoing to IVF/ICSI or egg donors, with the therapeutic intervention being corifollitropin alfa versus rFSH.…”

Section: Meterials and Methodsmentioning

confidence: 99%

“…The effectiveness and safety of corifollitropin alfa in comparison to rFSH have been the subject of several randomized controlled trials (RCTs). Previous meta-analyses [10, 11] have performed analysis on studies published up to 2011. The present paper aims to provide an updated meta-analysis on the corifollitropin alfa in IVF.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis

2015

View full text Add to dashboard Cite

The present study offers a meta-analysis of published randomized controlled trials (RCTs) evaluating the outcomes of in vitro fertilization (IVF) cycles using corifollitropin alfa for controlled ovarian stimulation (COS) in comparison with daily recombinant FSH (rFSH). The study examined seven RCTs including 2138 patients receiving corifollitropin alfa and 1788 women receiving daily rFSH for COS. As a novel aspect, this meta-analysis included two specific subpopulations of IVF patients, i.e. egg donors and poor responders. There were no significant differences between corifollitropin alfa and rFSH with respect to the majority of the clinical parameters considered, and comparable were the outcomes in terms of live birth rate, ongoing pregnancy rate, and clinical pregnancy rate. Women receiving corifollitropin alfa had a significantly higher number of metaphase II oocytes at ovum pick-up, and number of formed embryos, in comparison to rFSH. The risk of cycle cancellation due to overstimulation was significantly higher in the corifollitropin alfa group. Ovarian hyperstimulation syndrome (OHSS) incidence was statistically comparable between patients receiving long lasting or daily rFSH. Nevertheless, in view of the fact that corifollitropin alfa resulted in a higher number of metaphase II oocytes collected and a higher number of cycles cancelled due to overstimulation, corifollitropin alfa should be cautiously considered in women with the potential of being hyper responders.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Meterials and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis

2015

View full text Add to dashboard Cite

show abstract

“…Moreover, the reduction of the number of daily subcutaneous injections of gonadotropins could reduce the physical and psychological burdens for these patients. These theories must encourage researchers to perform controlled randomized trials to validate this original ovarian stimulation regimen without significant risk of OHSS as observed in good prognosis patients [76]. …”

Section: Is There An Ideal Protocol?mentioning

confidence: 99%

Management of Poor Responders in IVF: Is There Anything New?

Ubaldi

Vaiarelli²,

D’Anna³

et al. 2014

BioMed Research International

128

View full text Add to dashboard Cite

Despite the fact that in the last two decades an enormous number of papers on the topic of poor ovarian response have been published in the literature, so far it has been impossible to identify any efficient treatment to improve the ovarian response and the clinical outcome of this group of patients. The incidence of poor ovarian responders among infertile women has been estimated at 9–24% but according to recent reviews, it seems to have slightly increased. The limitation in quantifying the incidence of these patients among the infertile population is due to the difficulty of a clear definition in literature. A recent paper by the Bologna ESHRE working group on poor ovarian response has been the first real attempt to find a common definition. Current literature proposes new risk factors which could be the cause of a reduction in ovarian reserve, which also includes genetic factors. This represents the first necessary step towards finding applicable solutions for these patients. To date, there is a substantial lack of literature that identifies an ideal protocol for these patients. The use of the “Bologna criteria” and the introduction of long acting gonadotropin in clinical practice have given rise to new promising stimulation protocols for this group of patients.

show abstract

“…A single injection of CA is capable of initiating follicular growth and sustaining it for a week with a slow absorption reaching maximal concentrations two days after the injection and declining progressively afterwards (Bouloux et al ., 2001; Duijkers et al ., 2002; Fauser et al ., 2009; 2010; Devroey et al ., 2004). Previous studies revealed that 100 mcg of CA is the optimal dose for women up to 60 kg and 150 mcg for women over 60 kg (Devroey et al ., 2009; The Corifollitropin alfa ENSURE study group, 2010), initial studies demonstrated that the use of CA is highly effective and safe for ovarian stimulation, when used with Gonadotropin-Releasing Hormone (GnRH) antagonist (Kolibianakis et al ., 2006; Mahmoud Youssef et al ., 2012). This activity, when used with the long-term protocol could be considered a risk factor for Ovarian Hyperstimulation Syndrome (OHSS).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol

Salgueiro¹,

Rolim²,

Moura³

et al. 2016

JBRA Assisted Reproduction

View full text Add to dashboard Cite

ObjectiveThis study evaluated the use of Corifollitropin alfa in patients with previous poor response to recombinant follicle stimulating hormone in long-term protocols using gonadotropin-releasing hormone.MethodsTwenty-seven poor responders to previous treatment with the long term protocol using the recombinant follicle stimulating hormone (Group 1) were selected and then submitted to a second attempt using the same long term protocol with Corifollitropin alfa instead of the recombinant follicle stimulating hormone (Group 2).Ovarian down-regulation was achieved using subcutaneous administration of Leuprolide Acetate. Ovarian stimulation was performed with recombinant follicle stimulating hormone until the administration of human chorionic gonadotropin, followed by follicular aspiration (Group 1). Group 2 was submitted to this same protocol using Corifollitropin alfa instead of recombinant follicle stimulating hormone.ResultsThere were significant differences in the number of aspirated oocytes, percentage of mature oocytes, amount of injected oocytes and transferred embryos - with all of these parameters being increased in the Corifollitropin alfa group. In addition, the rates of pregnancy and ongoing pregnancy were also significantly higher in the Corifollitropin alfa group.ConclusionThe present study demonstrated that the use of Corifollitropin alfa in the long-term protocol could be a highly effective alternative for patients with poor ovarian response, who were unsuccessful in a previous treatment with In Vitro Fertilization - Intracytoplasmic Sperm Injection.

show abstract

Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis

Cited by 44 publications

References 27 publications

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis

Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis

Management of Poor Responders in IVF: Is There Anything New?

Evaluation of results obtained with corifollitropin alfa after poor ovarian response in previous cycle using recombinant follicular stimulating hormone in the long-term protocol

Contact Info

Product

Resources

About